Overview

A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis （EGPA）

Status:
Recruiting
Trial end date:
2027-05-16
Target enrollment:
Participant gender:
Summary
This study is a phase 2/3 clinical trial to evaluate the efficacy and safety of SHR-1703 in patients with EGPA.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Guangdong Hengrui Pharmaceutical Co., Ltd